IONS
Income statement / Annual
Last year (2023), Ionis Pharmaceuticals, Inc.'s total revenue was $787.65 M,
an increase of 34.18% from the previous year.
In 2023, Ionis Pharmaceuticals, Inc.'s net income was -$366.29 M.
See Ionis Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$787.65 M
|
$587.00 M
|
$810.00 M
|
$729.00 M
|
$1.12 B
|
$599.67 M
|
$507.67 M
|
$346.62 M
|
$283.70 M
|
$214.16 M
|
| Cost of Revenue |
$9.13 M |
$14.00 M |
$11.00 M |
$12.00 M |
$4.00 M |
$1.82 M |
$374.64 M |
$344.32 M |
$322.29 M |
$241.75 M |
| Gross Profit |
$778.51 M |
$573.00 M |
$799.00 M |
$717.00 M |
$1.12 B |
$597.85 M |
$133.02 M |
$2.30 M |
-$38.59 M |
-$27.59 M |
| Gross Profit Ratio |
0.99 |
0.98 |
0.99 |
0.98 |
1 |
1 |
0.26 |
0.01 |
-0.14 |
-0.13 |
| Research and Development
Expenses |
$899.63 M
|
$833.00 M
|
$643.00 M
|
$535.00 M
|
$466.00 M
|
$414.60 M
|
$374.64 M
|
$344.32 M
|
$322.29 M
|
$241.75 M
|
| General & Administrative
Expenses |
$232.60 M
|
$150.30 M
|
$170.90 M
|
$354.00 M
|
$287.00 M
|
$244.62 M
|
$108.49 M
|
$48.62 M
|
$37.17 M
|
$20.14 M
|
| Selling & Marketing
Expenses |
$0.00
|
$700,000.00
|
$15.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$232.60 M
|
$151.00 M
|
$186.00 M
|
$354.00 M
|
$287.00 M
|
$244.62 M
|
$108.49 M
|
$48.62 M
|
$37.17 M
|
$20.14 M
|
| Other Expenses |
$19,000.00 |
$3.00 M |
$9.00 M |
$2.00 M |
-$686,000.00 |
-$182,000.00 |
-$3.55 M |
$18.42 M |
$40.93 M |
$39.24 M |
| Operating Expenses |
$779.59 M |
$984.00 M |
$829.00 M |
$889.00 M |
$753.00 M |
$659.23 M |
$483.13 M |
$392.94 M |
$359.47 M |
$261.89 M |
| Cost And Expenses |
$1.14 B |
$998.00 M |
$840.00 M |
$901.00 M |
$757.00 M |
$661.05 M |
$483.13 M |
$392.94 M |
$359.47 M |
$261.89 M |
| Interest Income |
$0.00 |
$25.33 M |
$10.04 M |
$30.56 M |
$52.21 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$8.12 M |
$4.30 M |
$44.99 M |
$49.00 M |
$44.79 M |
$44.75 M |
$38.80 M |
$36.73 M |
$22.21 M |
| Depreciation &
Amortization |
$22.50 M
|
$22.11 M
|
$19.56 M
|
$17.16 M
|
$15.99 M
|
$12.53 M
|
$8.35 M
|
$9.03 M
|
$10.24 M
|
$9.40 M
|
| EBITDA |
-$230.01 M
|
-$227.76 M
|
-$239,000.00
|
-$107.88 M
|
$411.53 M
|
-$18.84 M
|
$39.80 M
|
-$8.83 M
|
-$40.94 M
|
-$22.78 M
|
| EBITDA Ratio |
-0.29 |
-0.96 |
-0.03 |
-0.24 |
0.33 |
-0.1 |
0.04 |
-0.13 |
-0.2 |
-0.13 |
| Operating Income Ratio
|
-0.45
|
-0.7
|
-0.04
|
-0.24
|
0.33
|
-0.1
|
0.05
|
-0.13
|
-0.27
|
-0.22
|
| Total Other
Income/Expenses Net |
$19.77 M
|
$152.21 M
|
$1.04 M
|
$37.53 M
|
-$27.12 M
|
-$14.78 M
|
-$47.81 M
|
-$37.31 M
|
-$12.14 M
|
-$6.66 M
|
| Income Before Tax |
-$333.97 M |
-$258.00 M |
-$30.00 M |
-$170.00 M |
$347.00 M |
-$76.16 M |
-$23.28 M |
-$83.62 M |
-$87.91 M |
-$54.39 M |
| Income Before Tax Ratio
|
-0.42
|
-0.44
|
-0.04
|
-0.23
|
0.31
|
-0.13
|
-0.05
|
-0.24
|
-0.31
|
-0.25
|
| Income Tax Expense |
$32.32 M |
$12.00 M |
-$1.00 M |
$317.00 M |
$44.00 M |
-$291.14 M |
-$5.98 M |
$2.93 M |
$372,000.00 |
-$15.41 M |
| Net Income |
-$366.29 M |
-$270.00 M |
-$29.00 M |
-$487.00 M |
$294.00 M |
$273.74 M |
-$5.97 M |
-$86.56 M |
-$88.28 M |
-$38.98 M |
| Net Income Ratio |
-0.47 |
-0.46 |
-0.04 |
-0.67 |
0.26 |
0.46 |
-0.01 |
-0.25 |
-0.31 |
-0.18 |
| EPS |
-2.56 |
-1.9 |
-0.21 |
-3.49 |
2.1 |
2.07 |
-0.0481 |
-0.72 |
-0.74 |
-0.33 |
| EPS Diluted |
-2.56 |
-1.9 |
-0.21 |
-3.49 |
2.06 |
2.04 |
-0.0473 |
-0.72 |
-0.74 |
-0.33 |
| Weighted Average Shares
Out |
$143.19 M
|
$141.85 M
|
$141.02 M
|
$139.61 M
|
$140.00 M
|
$132.32 M
|
$124.02 M
|
$120.80 M
|
$119.29 M
|
$117.69 M
|
| Weighted Average Shares
Out Diluted |
$143.19 M
|
$141.85 M
|
$141.02 M
|
$139.61 M
|
$142.87 M
|
$134.06 M
|
$126.10 M
|
$120.93 M
|
$119.72 M
|
$117.69 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
